Literature DB >> 21989092

Dapagliflozin--redefining treatment of T2DM?

Edward C Chao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21989092     DOI： 10.1038/nrendo.2011.177

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  5 in total

1.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

Authors:  K Strojek; K H Yoon; V Hruba; M Elze; A M Langkilde; S Parikh
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

2.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

Authors:  Clifford J Bailey; Jorge L Gross; Anne Pieters; Arnaud Bastien; James F List
Journal:  Lancet       Date:  2010-06-26       Impact factor: 79.321

3.  Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Authors:  Ele Ferrannini; Silvia Jimenez Ramos; Afshin Salsali; Weihua Tang; James F List
Journal:  Diabetes Care       Date:  2010-06-21       Impact factor: 19.112

4.  Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Authors:  Michael A Nauck; Stefano Del Prato; Juris J Meier; Santiago Durán-García; Katja Rohwedder; Martina Elze; Shamik J Parikh
Journal:  Diabetes Care       Date:  2011-08-04       Impact factor: 19.112

5.  Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 17.152
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.